Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 95INDUSTRY 83NETWORK 6OTHER_GOV 3NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Carcinoma, Squamous Cell 1

Interventions

Cisplatin 50Capecitabine 42apatinib 34Radiotherapy 33Oxaliplatin 33Gemcitabine 33Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 21Nivolumab 19pembrolizumab 18fludarabine 18Radiation 16Metformin 16Exercise 16camrelizumab 15S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Afatinib × Clear all
NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Shandong Public Health Clinical Center

Phase 2 Recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01156545 2022-04-06

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

National Cancer Center, Korea

Phase 2 Completed
68 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03486509 2018-04-03

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

Fujian Cancer Hospital

Phase 2 Unknown
2 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡